1-3 of 3
Gordon Bray
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

Monteserrat Arnan, Anand Ashwin Patel, Jordi Esteve, Lawrence Morris, Gary J. Schiller, Ronan T. Swords, Juan M. Alonso-Dominguez, Laura C. Michaelis, Naval Daver, Luis A. Carvajal, Gordon Bray, Elizabeth Olek, Richard E. Cutler, Jorge F. DiMartino, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 5973.
https://doi.org/10.1182/blood-2023-178804
Published: 2023
Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

John C. Byrd, Jorge E. Cortes, Mark D. Minden, Thomas Oellerich, Eytan M. Stein, Jenna Elder, Pavan Kumar, Gordon Bray, Jorge DiMartino, Wendy Stock
Journal: Blood
Blood (2021) 138 (Supplement 1): 1282.
https://doi.org/10.1182/blood-2021-145773
Published: 2021
Journal Articles

The Inhibitor Antibody Response Is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs With Factor VIII Autoantibodies

Richard Prescott, Hiroaki Nakai, Evgueni L. Saenko, Inge Scharrer, Inga Marie Nilsson, John E. Humphries, Deborah Hurst, Gordon Bray, Dorothea Scandella, the Recombinate and Kogenate Study Groups
Journal: Blood
Blood (1997) 89 (10): 3663–3671.
https://doi.org/10.1182/blood.V89.10.3663
Published: 1997